JOP20210266A1 - مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية - Google Patents

مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية

Info

Publication number
JOP20210266A1
JOP20210266A1 JOP/2021/0266A JOP20210266A JOP20210266A1 JO P20210266 A1 JOP20210266 A1 JO P20210266A1 JO P20210266 A JOP20210266 A JO P20210266A JO P20210266 A1 JOP20210266 A1 JO P20210266A1
Authority
JO
Jordan
Prior art keywords
urothelial carcinoma
fgfr
treatment
tyrosine kinase
kinase inhibitors
Prior art date
Application number
JOP/2021/0266A
Other languages
Arabic (ar)
English (en)
Inventor
Anjali Narayan Avadhani
Anne Elizabeth O'hagan
Ademi Elena Santiago-Walker
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20210266A1 publication Critical patent/JOP20210266A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JOP/2021/0266A 2019-03-29 2021-09-26 مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية JOP20210266A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166428 2019-03-29
EP19188971 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
JOP20210266A1 true JOP20210266A1 (ar) 2023-01-30

Family

ID=70296138

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0266A JOP20210266A1 (ar) 2019-03-29 2021-09-26 مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية

Country Status (15)

Country Link
US (1) US12691112B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946341A1 (cg-RX-API-DMAC7.html)
JP (2) JP7747521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210145211A (cg-RX-API-DMAC7.html)
CN (1) CN113645974A (cg-RX-API-DMAC7.html)
AU (1) AU2020253827B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019446A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130460A1 (cg-RX-API-DMAC7.html)
IL (1) IL286729A (cg-RX-API-DMAC7.html)
JO (1) JOP20210266A1 (cg-RX-API-DMAC7.html)
MA (1) MA55522A (cg-RX-API-DMAC7.html)
MX (1) MX2021011926A (cg-RX-API-DMAC7.html)
PH (1) PH12021552342A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109902SA (cg-RX-API-DMAC7.html)
WO (1) WO2020205493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12277100B2 (en) * 2019-09-12 2025-04-15 Life Spectacular, Inc. Maintaining user privacy of personal, medical, and health care related information in recommendation systems
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
KR20210064274A (ko) 2018-09-21 2021-06-02 얀센 파마슈티카 엔.브이. 담관암종의 치료
BR112021015686A2 (pt) 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
US20220175768A1 (en) 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Also Published As

Publication number Publication date
US12691112B2 (en) 2026-07-28
CN113645974A (zh) 2021-11-12
JP2025156297A (ja) 2025-10-14
MX2021011926A (es) 2021-11-03
AU2020253827B2 (en) 2026-01-08
JP7747521B2 (ja) 2025-10-01
EP3946341A1 (en) 2022-02-09
PH12021552342A1 (en) 2022-08-22
KR20210145211A (ko) 2021-12-01
AU2020253827A1 (en) 2021-09-30
IL286729A (en) 2021-10-31
WO2020205493A1 (en) 2020-10-08
US20220054484A1 (en) 2022-02-24
MA55522A (fr) 2022-02-09
SG11202109902SA (en) 2021-10-28
CA3130460A1 (en) 2020-10-08
JP2022527189A (ja) 2022-05-31
BR112021019446A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
WO2021195782A8 (en) Methods of using myt1 inhibitors
SV2017005415A (es) Uso de paneles de genes mutantes fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor fgfr
ZA202306559B (en) Indazole compounds as kinase inhibitors
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
ZA202204284B (en) Inhibitors of raf kinases
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
MX2024004162A (es) Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico.
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
PH12021552342A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
PH12021552352A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
EA201791236A1 (ru) Применение ингибиторов пан fgfr и способ идентификации пациентов, заболевших раком, для лечения с помощью ингибитора пан fgfr
ZA202103975B (en) Methods of treating disease with magl inhibitors
BR112023022530A2 (pt) Inibidores de pcna e inibidores de egfr para tratamento de câncer
EA201991091A1 (ru) Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
IL290798A (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
JOP20220181A1 (ar) مثبطات كيناز تيروسين fgfr وعوامل مضادة لـ pd1 لعلاج كارسينوما الظهارة البولية
MX2021008865A (es) Inhibidores de magl para usarse para tratar enfermedades antecedentes.
EA202192656A1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
MX2022009447A (es) Uso de inhibidores de micro ácido ribonucleico 485 (miarn 485) para tratamiento de tauopatía.
Hu et al. Rapid and Effective Neuronal Conversion of Human Glioblastoma In Vitro and In Vivo Using Potent Small Molecules
PH12021550628A1 (en) Treatment of cholangiocarcinoma
AR122377A1 (es) Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial
JOP20230213A1 (ar) مثبطات حلقية غير متجانسة لكيناز البروتين المتفاعل مع المستقبل-1
WO2023278787A3 (en) Treatment of decreased bone mineral density with wnt family member 5b (wnt5b) inhibitors